Plus Therapeutics (NASDAQ:PSTV) Trading Down 3.2% – What’s Next?

Plus Therapeutics, Inc. (NASDAQ:PSTV) shares fell 3.2% during trading on Tuesday . The stock traded as low as $3.90 and last traded at $3.92. Approximately 84,374 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 212,309 shares. The stock had previously closed at $4.05.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PSTV. D. Boral Capital reaffirmed a “hold” rating on shares of Plus Therapeutics in a report on Tuesday, March 31st. Wall Street Zen upgraded shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. Finally, Ascendiant Capital Markets lowered their price target on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $56.40.

Plus Therapeutics Stock Performance

The stock’s 50-day moving average price is $5.32 and its 200-day moving average price is $6.96. The company has a market capitalization of $26.97 million, a price-to-earnings ratio of -1.70 and a beta of 1.40.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.20). The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.97 million. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. Analysts anticipate that Plus Therapeutics, Inc. will post -3.76 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of Plus Therapeutics during the 2nd quarter worth $41,000. Susquehanna International Group LLP acquired a new stake in Plus Therapeutics in the 3rd quarter valued at about $46,000. Scientech Research LLC acquired a new stake in Plus Therapeutics in the 3rd quarter valued at about $100,000. XTX Topco Ltd purchased a new position in Plus Therapeutics during the 4th quarter valued at about $127,000. Finally, State Street Corp increased its holdings in Plus Therapeutics by 37.1% during the 4th quarter. State Street Corp now owns 468,893 shares of the company’s stock valued at $240,000 after acquiring an additional 127,000 shares in the last quarter. Hedge funds and other institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.